Literature DB >> 8769752

Adenosine A1 and A2 receptors mediate tone-dependent responses in feline pulmonary vascular bed.

D Y Cheng1, B J DeWitt, F Suzuki, C F Neely, P J Kadowitz.   

Abstract

Adenosine produces tone-dependent pulmonary vascular responses; however, the adenosine receptor subtype mediating these responses is unknown. In the present study, the adenosine receptor subtypes mediating tone-dependent responses were investigated, Intralobar injections of adenosine,ATP, and analogues under low-tone conditions caused dose-related increases in lobar arterial pressure; the order of potency was alpha,beta-methylene ATP (alpha,beta-metATP) > N6-cyclopentyladenosine (CPA) > ATP > adenosine. Under low-tone conditions, pressor responses to adenosine, ATP, and CPA, an adenosine A1-receptor agonist, were reduced by KW-3902, an adenosine A1-receptor antagonist, whereas KW-3902 and meclofenamate had no effect on responses to alpha,beta-metATP, norepinephrine, serotonin, or angiotensin II. Under elevated-tone conditions, injections of adenosine, ATP, and analogues caused dose-related decreases in lobar arterial pressure, and adenosine was 10-fold less potent than 5'-(N-cyclopropyl)-carboxamidoadenosine (CPCA), an A2-receptor agonist, and ATP. KF-17837, an A2-receptor antagonist, reduced vasodilator responses to adenosine and CPCA, whereas responses to ATP, isoproterenol, diethylamine-NO, lemakalim, and bradykinin were not changed. The vasodilator responses to adenosine were not attenuated by Nw-nitro-L-arginine benzyl ester, methylene blue, or U-37883A. These results suggest that vasoconstrictor responses to adenosine are mediated by A1 receptors and the release of vasoconstrictor prostanoids, and that, under elevated-tone conditions, vasodilator responses are mediated by A2 receptors but not the release of nitric oxide or the activation of guanylate cyclase or K+ATP channels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769752     DOI: 10.1152/ajpheart.1996.270.1.H200

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Crosstalk between Galpha(i)- and Galpha(q)-coupled receptors is mediated by Gbetagamma exchange.

Authors:  U Quitterer; M J Lohse
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

Review 2.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

Review 3.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

4.  Combined contribution of endothelial relaxing autacoides in the rat femoral artery response to CPCA: an adenosine A2 receptor agonist.

Authors:  Miroslav Radenković; Marko Stojanović; Radmila Janković; Mirko Topalović; Milica Stojiljković
Journal:  ScientificWorldJournal       Date:  2012-04-19

Review 5.  Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension.

Authors:  Allan K N Alencar; Guilherme C Montes; Eliezer J Barreiro; Roberto T Sudo; Gisele Zapata-Sudo
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

6.  Endogenously released adenosine causes pulmonary vasodilation during the acute phase of pulmonary embolization in dogs.

Authors:  Hiroko Takahama; Hiroshi Asanuma; Osamu Tsukamoto; Shin Ito; Masafumi Kitakaze
Journal:  Int J Cardiol Heart Vasc       Date:  2019-07-10

7.  Vasodepressor Effects of Adenosine in the Cat are Independent of Cyclooxygenase, Potassium Channels, and Nitric Oxide Pathways.

Authors:  Alan David Kaye; Syed R Baber; Mohammed T Sharief; Rachel J Kaye; Elyse M Cornett
Journal:  Drugs R D       Date:  2019-12

8.  ATP-sensitive muscle afferents activate spinal trigeminal neurons with meningeal afferent input in rat - pathophysiological implications for tension-type headache.

Authors:  Moritz Nöbel; Stephan Feistel; Jens Ellrich; Karl Messlinger
Journal:  J Headache Pain       Date:  2016-08-26       Impact factor: 7.277

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.